Skip to main content
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp — Investor Relations & Filings

Ticker · ABUS ISIN · CA03879J1003 US Manufacturing
Open in API
Filings indexed 1,014 across all filing types
Latest filing 2024-04-04 Regulatory Filings
Country US United States of America
Listing US ABUS

About Arbutus Biopharma Corp

https://www.arbutusbio.com/

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases, with a primary emphasis on creating a functional cure for chronic Hepatitis B virus (cHBV) infection. The company's strategy involves developing combination regimens that utilize multiple agents with complementary mechanisms of action. This approach aims to suppress viral replication, reduce viral antigens, and reawaken the host's immune response. A key candidate in its pipeline is imdusiran, an RNA interference (RNAi) therapeutic. Arbutus leverages its expertise in virology and drug delivery systems to advance its portfolio of clinical assets for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions an "Other Events" item regarding a claim construction ruling in a lawsuit and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (3605 characters). It is not an annual or quarterly report, nor a detailed earnings release or management discussion. The document serves as a regulatory announcement of a legal event and includes a press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-04-04 English
10-K
Annual Report FY 2023
2024-03-05 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated February 29, 2024. It reports the issuance of a press release announcing financial results for the fourth quarter and year ended December 31, 2023, and also mentions an updated corporate presentation posted on the company's website. The document itself is a current report notifying the market of these events rather than containing the full financial results or detailed financial statements. The length is 3665 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. The document references exhibits (press release and presentation) but does not include the full financial data or detailed analysis. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that announce events or provide notices without containing full reports themselves.
2024-02-29 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.